Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Valneva (NASDAQ:VALN – Free Report) had its target price trimmed by HC Wainwright from $18.00 to $17.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report.

In a report released on February 18, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...

Ratings for Valneva (NASDAQ:VALN) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

Valneva expects further sales growth this year after it posted higher revenue in 2024.

VALNEVA Declaration of shares and voting rights January 31, 2025_____ Company name: VALNEVARegistered office ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...